Innovent Biologics, Inc. is a prominent pharmaceutical company based in China, specializing in biotechnology. With an ESG score of 29.3, it is considered a medium-risk investment. Innovent has a strong presence in the market, with a focus on oncology products like Tyvyt, a PD-1 inhibitor. The company is listed on the Hong Kong Exchange and has numerous strategic collaborations with global pharmaceutical giants like Eli Lilly and Roche Group. In addition to its current products, Innovent is also developing promising therapies such as Mazdutide for obesity and type 2 diabetes.